本研究是在试图合成一类新的包括11种化合物(潜在的抗癌剂的情况下进行24 - 34共享3,5- diarylisoxazole作为芯)。通过IR,1 H NMR,13 C NMR和元素分析确定了新合成化合物的化学结构。通过使用癌症PC3细胞和非致瘤性PNT1a细胞评估了它们对前列腺癌的生物学潜力。有趣的是,化合物26与其他化合物的区别在于它具有相当高的选择性值,可与5-FU相比。装订方式26 通过基于GLIDE标准精度以及MM-GBSA计算的对接模拟,详细研究了针对核糖体蛋白S6激酶beta-1(S6K1)的核糖体蛋白。
Enantioselective Ring Opening of<i>meso</i>-Epoxides with Silicon Tetrachloride Catalyzed by Pyridine<i>N</i>-Oxides Fused with the Bicyclo[3.3.1]nonane Framework
作者:Algirdas Neniškis、Sigitas Stončius
DOI:10.1002/ejoc.201500762
日期:2015.10
chiral Lewis basic organocatalysts that contain pyridine N-oxide moieties fused with the bicyclo[3.3.1]nonane framework is reported. The obtained pyridine N-oxides were employed as catalysts in the enantioselective ring opening of meso-epoxides with silicon tetrachloride. Derivative 1b endowed with two 2,4-diaryl-substituted pyridine N-oxide moieties proved to be a particularly effective catalyst for desymmetrization
Design, synthesis and antiproliferative activity evaluation of fluorine-containing chalcone derivatives
作者:Serdar Burmaoglu、Derya Aktas Anil、Arzu Gobek、Deryanur Kilic、Derya Yetkin、Nizami Duran、Oztekin Algul
DOI:10.1080/07391102.2020.1848627
日期:2022.5.24
Abstract A series of new chalcones containing fluoro atom at B ring have been designed, synthesized, and evaluated to be antiproliferative activity against a panel of human tumorcell lines. Some of the analogs (8, 9, 12, 45, 46 and 48) displayed powerful antiproliferative effects to certain human tumorcells, but all of them were devoid of any cytotoxicity towards the normal HEK 293. Acridine orange
摘要 已经设计、合成了一系列在 B 环上含有氟原子的新查尔酮,并评估了它们对一组人类肿瘤细胞系的抗增殖活性。一些类似物(8、9、12、45、46和48)对某些人类肿瘤细胞显示出强大的抗增殖作用,但它们都对正常的 HEK 293 没有任何细胞毒性。吖啶橙染色数据支持细胞毒性合成的类似物对肿瘤细胞的抗增殖作用是通过细胞凋亡介导的。化合物12和46使用 xCELLigence 测定法在人肝细胞癌细胞系中表现出浓度依赖性抗增殖活性。化合物对微管蛋白的计算机分子对接研究进一步支持了结构和抗增殖活性的关系,这表明我们的化合物干扰细胞分裂。 由 Ramaswamy H. Sarma 传达
Design of potent fluoro-substituted chalcones as antimicrobial agents
作者:Serdar Burmaoglu、Oztekin Algul、Arzu Gobek、Derya Aktas Anil、Mahmut Ulger、Busra Gul Erturk、Engin Kaplan、Aylin Dogen、Gönül Aslan
DOI:10.1080/14756366.2016.1265517
日期:2017.1.1
resistance, we attempted to develop novel antitubercular and antimicrobialagents. For this purpose, we developed some new fluorine-substituted chalcone analogs (3, 4, 9-15, and 20-23) using a structure-activity relationship approach. Target compounds were evaluated for their antitubercular efficacy against Mycobacterium tuberculosis H37Rv and antimicrobial activity against five common pathogenic bacterial and
22 Flavokawain derivatives (FKd) were obtained by one step syntheses in order to conduct a SAR study to understand the structural requirements for optimum and selective cytotoxicity. FKd and natural flavokawains A and B found into kava, a South Pacific traditional beverage, were evaluated against nine cancer and one healthy cell lines. The targeted cell cycle phases as well as the effects on the induction of apoptosis and cell cycle protein levels were investigated. Therapeutic improvements (more activity and selectivity) were achieved with FKd compared to natural flavokawains and notably with the 2',3,4',6'-tetramethoxychalcone (FKd 19). FKd induced a Gl/S arrest on p53 wild-type cells and an M arrest on p53 mutant-type, via the up-regulation of p21 and cyclin B1 proteins, followed by apoptosis. Moreover, FKd exhibited a 24 h-effect on Akt/mTor normal cells versus a 48 h-effect on Akt/mTor up-regulated cells. The SAR study resulted in the conclusion that trimethoxy A-ring allowed the best compromise between cytotoxicity and selectivity, as well as the substitution of the meta position on the B-ring and the use of halogens substituents. (C) 2017 Elsevier Ltd. All rights reserved.
[EN] ESTROGEN RECEPTOR ALPHA COLIGANDS, AND METHODS OF USE THEREOF<br/>[FR] CO-LIGANDS DES RÉCEPTEURS DES OESTROGÈNES ALPHA ET LEURS PROCÉDÉS D'UTILISATION
申请人:UNIV CALIFORNIA
公开号:WO2017132135A1
公开(公告)日:2017-08-03
Provided herein is a coligand for the estrogen receptor (ER) α subunit, and methods of use thereof in treating conditions associated with ER signaling in an individual. The present ERα coligand may be a cell type-selective, allosteric modulator of ERα signaling. The ERα coligand, when administered to an individual, may modulate ER agonist-dependent signaling in a tissue-selective manner.